David A. Siegel Synlogic, Inc. Transaction History

Two Sigma Advisers, LP

$43.8 Billion
Q2 2024

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$0.42 - $0.68 $966 - $1,564	-2,300 Reduced 1.72%	131,100 $56,000
Q1 2023 May 15, 2023	SELL	$0.56 - $1.07 $4,648 - $8,881	-8,300 Reduced 5.86%	133,400 $84,000
Q4 2022 Feb 14, 2023	SELL	$0.58 - $17.99 $5,858 - $181,698	-10,100 Reduced 6.65%	141,700 $107,000
Q3 2022 Nov 14, 2022	SELL	$0.91 - $14.63 $1,820 - $29,260	-2,000 Reduced 1.3%	151,800 $144,000
Q2 2022 Aug 15, 2022	SELL	$0.89 - $2.47 $11,036 - $30,628	-12,400 Reduced 7.46%	153,800 $177,000
Q1 2022 May 16, 2022	SELL	$1.63 - $2.55 $355,340 - $555,900	-218,000 Reduced 56.74%	166,200 $399,000
Q4 2021 Feb 14, 2022	SELL	$2.27 - $3.0 $42,449 - $56,100	-18,700 Reduced 4.64%	384,200 $930,000
Q3 2021 Nov 15, 2021	SELL	$2.45 - $4.1 $698,005 - $1.17 Million	-284,900 Reduced 41.42%	402,900 $1.23 Million
Q2 2021 Aug 16, 2021	BUY	$3.0 - $4.39 $205,200 - $300,276	68,400 Added 11.04%	687,800 $2.68 Million
Q1 2021 May 17, 2021	BUY	$2.2 - $5.05 $407,220 - $934,755	185,100 Added 42.62%	619,400 $2.22 Million
Q4 2020 Feb 16, 2021	BUY	$1.85 - $2.54 $263,440 - $361,696	142,400 Added 48.78%	434,300 $938,000
Q3 2020 Nov 16, 2020	SELL	$1.85 - $2.57 $65,860 - $91,492	-35,600 Reduced 10.87%	291,900 $590,000
Q2 2020 Aug 14, 2020	BUY	$1.59 - $2.51 $6,360 - $10,040	4,000 Added 1.24%	327,500 $665,000
Q1 2020 May 15, 2020	BUY	$1.39 - $3.19 $159,294 - $365,574	114,600 Added 54.86%	323,500 $556,000
Q4 2019 Feb 14, 2020	BUY	$1.96 - $2.81 $367,696 - $527,156	187,600 Added 880.75%	208,900 $539,000
Q3 2019 Nov 14, 2019	BUY	$2.12 - $9.37 $45,156 - $199,580	21,300 New	21,300 $49,000

Others Institutions Holding SYBX

# of Institutions

Shares Held

25.5K

Call Options Held

Put Options Held

View Full List

About SYNLOGIC, INC.

Ticker SYBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,229,600
Market Cap $103M
Description
Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotic medicines to treat metabolic and immunological diseases in the United States. Its therapeutic programs include SYNB1618 and SYNB1934 that are orally administered, non-systemically absorbed drug candidates, which are in Phase I...

More about SYBX

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account